Sanofi/Regeneron's Sarilumab Faces Stiff Competition Despite Humira Triumph
This article was originally published in Scrip
Regeneron/Sanofi's IL-6 inhibitor sarilumab has beaten AbbVie's Humira (adalimumab) in a head to head trial. Top line Phase III results show sarilumab more significantly improved the signs and symptoms of rheumatoid arthritis after 24 weeks of treatment than blockbusting Humira did. The data will help differentiate the drug, but competition will remain fierce in the RA space, say analysts.
You may also be interested in...
Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at what to expect before we enter the new year.
Important updates to good manufacturing practice guidelines are likely to mean medicine shortages, warns a German pharmaceutical industry group.
The IGBA has welcomed Mexican pharmaceutical industry association ANAFAM as an associate member.